Pharmaceutical innovation and access to financial markets.
While prior research shows that pharmaceutical innovation generates measurable benefits for society, over the last 70 years, the innovative activities of pharmaceutical firms have dramatically declined. In this study, we develop and test the hypothesis that to innovate, pharmaceutical firms must hav...
Main Authors: | Benjamin M Blau, Todd G Griffith, Ryan J Whitby |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0278875 |
Similar Items
-
Pharmaceutical innovation and access to financial markets
by: Benjamin M. Blau, et al.
Published: (2022-01-01) -
Range-based volatility, expected stock returns, and the low volatility anomaly.
by: Benjamin M Blau, et al.
Published: (2017-01-01) -
INNOVATIVE PROCESSES IN THE RUSSIAN PHARMACEUTICAL MARKET
by: E. A. Bykova
Published: (2020-09-01) -
Pharmaceutical market access in emerging markets: concepts, components, and future
by: Anuj Kumar, et al.
Published: (2014-12-01) -
Equity of access to innovative drugs and sustainability of pharmaceutical expenditure
by: Mario Eandi
Published: (2010-06-01)